Related Experiment Videos
Carbamyl phosphate synthetase 1 deficiency: a destructive encephalopathy
M Takeoka1, T B Soman, V E Shih
1Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Pediatric Neurology
|April 13, 2001
Summary
Carbamyl phosphate synthetase I deficiency causes hyperammonemic encephalopathy in newborns. This urea cycle disorder leads to severe brain damage, especially during hyperammonemic crises, and is challenging to treat.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Neurology
Background:
- Carbamyl phosphate synthetase I (CPS1) is a key enzyme in the urea cycle.
- CPS1 deficiency is an inborn error of metabolism leading to hyperammonemia.
- Early diagnosis and management are crucial for patient outcomes.
Observation:
- Neonatal-onset CPS1 deficiency presents as hyperammonemic encephalopathy with altered consciousness and seizures.
- Later-onset or partial deficiencies can manifest with fluctuating neurological deficits.
- Neuroimaging and pathology reveal destructive encephalopathy, cerebral edema, atrophy, and cystic changes.
Findings:
- Hyperammonemic crises precipitate neurological deterioration in CPS1 deficiency.
- The severity of neurological damage correlates with ammonia levels and enzyme activity.
- Three cases illustrate the progressive neurotoxicity and neuropathological consequences of CPS1 deficiency.
Implications:
- Effective treatment strategies for CPS1 deficiency remain challenging, particularly for neonatal forms.
- Understanding the neurobiological impact of hyperammonemia is vital for developing targeted therapies.
- Improved diagnostic and therapeutic approaches are needed to mitigate the severe neurological sequelae of CPS1 deficiency.